Weisser Martin, Tischer Johanna, Schnittger Susanne, Schoch Claudia, Ledderose Georg, Kolb Hans Jochem
Department of Internal Medicine III, University of Munich, Klinikum Grosshadern, Munich, Germany.
Haematologica. 2006 May;91(5):663-6. Epub 2006 Apr 19.
Imatinib mesylate is highly effective in relapsed chronic myelogenous leukemia (CML) after allogeneic hematopoetic stem cell transplantation (HSCT). However, it is unknown whether imatinib produces durable molecular remissions. The outcome of CML patients transplanted at our center who had received only imatinib for relapse after HSCT was compared with that of patients treated with donor lymphocyte infusions (DLI). Imatinib therapy resulted in a higher incidence of relapse and inferior leukemia-free survival (p=0.006 and p=0.016, respectively). These data suggest that imatinib alone probably does not cure relapse after HSCT.
甲磺酸伊马替尼对异基因造血干细胞移植（HSCT）后复发的慢性粒细胞白血病（CML）疗效显著。然而，伊马替尼是否能产生持久的分子学缓解尚不清楚。将在我们中心接受HSCT后复发且仅接受伊马替尼治疗的CML患者的结局与接受供体淋巴细胞输注（DLI）治疗的患者的结局进行了比较。伊马替尼治疗导致更高的复发率和更低的无白血病生存率（分别为p = 0.006和p = 0.016）。这些数据表明，单独使用伊马替尼可能无法治愈HSCT后的复发。
